Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sosei Balances R&D Risk with 7 Compounds in Pipeline
September 8, 2003
- AstraZeneca to Build Marketing System in CNS Field via Zomig
September 8, 2003
- Candesartan Reduces Chronic Heart Failure: ESC Meeting
September 8, 2003
- Asahi Kasei Pharma to Specialize in Brain/CNS, Urology, Bones
September 8, 2003
- Takara Bio Succeeds in Enhancing Production of Activated Lymphocytes
September 8, 2003
- CROs Prefer Experienced People Over New Grads: Survey
September 8, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 8, 2003
- BUSINESS NEWS IN BRIEF
September 8, 2003
- Press Seminar
September 8, 2003
- New Waves in the Generic Drug Industry (1)
September 8, 2003
- NEW PRODUCTS
September 8, 2003
- Financial Results in 1st Quarter
September 8, 2003
- MEDICAL DEVICE NEWS IN BRIEF
September 8, 2003
- Korosho Budget Request for 2004 Totals \20 Trillion
September 8, 2003
- OTC NEWS IN BRIEF
September 8, 2003
- Korosho Calls For Attention to ADRs due to Tamiflu, Diovan
September 8, 2003
- Korosho to Revise Priority NDA Review System
September 8, 2003
- Reductions in NHI Prices, Medical Fees Inevitable in 2004
September 8, 2003
- REGULATORY NEWS IN BRIEF
September 8, 2003
- GE Use at National Hospitals Increasing Steadily: Survey
September 8, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…